NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messerli FH. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. American Journal of Cardiology 2013; 112(8): 1230-1234. [PubMed: 23827403]
Abstract
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid MEDLINE, PubMed, and Excerpta Medica (EMBASE) was searched up to October 2012. Four trials, in 3,917 patients, comparing cilostazol with aspirin were identified. Compared with aspirin, cilostazol was associated with a 73% reduction in hemorrhagic stroke (relative risk [RR] 0.27, 95% confidence interval [CI] 0.13 to 0.54, p = 0.0002), 28% reduction in the composite end point of stroke, myocardial infarction, or vascular death (RR 0.72, 95% CI 0.57 to 0.89, p = 0.003), and 48% reduction in total hemorrhagic events (RR 0.52, 95% CI 0.34 to 0.79, p = 0.002), with trend for lesser gastrointestinal bleeds (RR 0.60, 95% CI 0.34 to 1.06, p = 0.08). In conclusion, compared with aspirin, cilostazol is associated with significantly less hemorrhagic stroke, the combined end point of stroke, myocardial infarction, and vascular death, and total hemorrhagic events, with numerically fewer gastrointestinal bleeds when used for the secondary prevention of stroke.
Copyright © 2013 Elsevier Inc. All rights reserved.
- Review Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.[Cochrane Database Syst Rev. 2011]Review Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.Kamal AK, Naqvi I, Husain MR, Khealani BA. Cochrane Database Syst Rev. 2011 Jan 19; 2011(1):CD008076. Epub 2011 Jan 19.
- Review Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.[Cerebrovasc Dis. 2015]Review Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.Zhang Q, Wang C, Zheng M, Li Y, Li J, Zhang L, Shang X, Yan C. Cerebrovasc Dis. 2015; 39(1):13-22. Epub 2014 Dec 24.
- Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.[J Stroke Cerebrovasc Dis. 2021]Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.Lin MP, Meschia JF, Gopal N, Barrett KM, Ross OA, Ertekin-Taner N, Brott TG. J Stroke Cerebrovasc Dis. 2021 Mar; 30(3):105581. Epub 2020 Dec 31.
- Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.[Int J Stroke. 2015]Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T, CSPS.com Study Investigators. Int J Stroke. 2015 Feb; 10(2):253-8. Epub 2014 Dec 8.
- Review Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.[Cochrane Database Syst Rev. 2003]Review Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.De Schryver EL, Algra A, van Gijn J. Cochrane Database Syst Rev. 2003; (1):CD001820.
- Meta-analysis of cilostazol versus aspirin for the secondary prevention of strok...Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
- Pseudomonas viridiflava strain ICMP 3272 PvrICMP3272_Contig_4, whole genome shot...Pseudomonas viridiflava strain ICMP 3272 PvrICMP3272_Contig_4, whole genome shotgun sequencegi|1502636801|ref|NZ_RBQZ01000092.1 |WGS:NZ_RBQZ01|PvrICMP3272_Contig_4Nucleotide
- JGI_CAAP10610.rev NIH_XGC_tropInt1 Xenopus tropicalis cDNA clone IMAGE:7716808 3...JGI_CAAP10610.rev NIH_XGC_tropInt1 Xenopus tropicalis cDNA clone IMAGE:7716808 3', mRNA sequencegi|58791624|gnl|dbEST|27685016|gb|C 02.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...